# ContextOps Validation Report

## Validation Target

- Artifact: `zelostat-marktanalyse-context-packet-v0-1.md`
- Version: 0.1
- Producer: `marktanalyse`
- Intended consumers: `buying-contexts`, `segmentation-strategy`
- Validation cycle: Initial validation

## Applied Contracts And Profiles

- Universal ContextOps Handoff Contract
- Primary profile: Market Context
- Evidence and provenance rules
- Regulated/sensitive claim-risk overlay
- Downstream handoff usability
- B2B professional-consumable lens, with regulatory status unconfirmed

## Verdict

REVISE

## Findings

| ID | Severity | Category | Location | Evidence | Required correction | Owner |
|---|---|---|---|---|---|---|
| EVD-01 | major | Evidence, provenance, citation, or uncertainty | `Category Context`; `Competitor And Substitute Clusters`, especially the core-market range and named Sterican, MicronJet and Mesoram examples | The packet does not map individual labels and examples to exact sources. Several details are not supported by the supplied summaries or evidence extract, including the `33G–35G` core range, Luer/Luer-lock compatibility, and the named Sterican, MicronJet and Mesoram examples. The current high-level evidence ledger cannot distinguish sourced facts from plausible additions. | Add claim-level source references and evidence status for category labels, boundaries and named examples. Remove unsupported examples or label them explicitly as unverified evidence leads. | producer |
| EVD-02 | major | Evidence, provenance, citation, or uncertainty | `Minimal Market Dynamics`, rows on hub fit, documentation-driven adoption, and procurement convenience | Competitor product architecture supports the existence of comparison language, but not that these factors materially shape adoption. Likewise, single-use instructions do not establish that regulatory documentation drives purchasing, and visible pricing does not establish procurement convenience as a market dynamic. These are reasonable hypotheses presented with stronger status than the evidence supports. | Separate observed category facts from inferred market dynamics. Label adoption, purchasing importance and switching relevance as hypotheses pending customer, procurement or sales evidence. | producer |
| CLM-01 | major | Claim risk or allowed use | `Business-Model Lens`; `Minimal Market Dynamics`; `Evidence Status`; `Context Packet Summary` | The packet describes Zelostat as a professional medical consumable and invokes regulated-product documentation while regulatory identity, intended use and conformity remain unverified. Sensitive claims concerning savings, comfort, bruising and adverse events are acknowledged but not assigned explicit risk levels or atomic allowed-use constraints. | State that medical-device/regulatory status is unconfirmed. Apply an explicit regulated/sensitive overlay that separates the savings, flow, comfort, bruising and adverse-event claims; identify their risk, current evidence strength and permitted use. Restrict them to internal hypotheses or evidence-gap framing until substantiated. | producer |
| CTR-01 | minor | Contract or required structure | `Produces Context For` | The contract requires an explicit `Produces` inventory. The section identifies consumers and general uses but does not enumerate the packet’s handed-off fields. | Add a concise `Produces` list covering market definition, boundaries, category context, alternative clusters, dynamics, evidence ledger and handoff questions. | producer |
| EVD-03 | minor | Evidence, provenance, citation, or uncertainty | `Working Market Definition`; `Context Packet Summary` | Germany is supported by current distribution evidence, while wider European commercial coverage is explicitly unverified. The summary wording nevertheless presents a combined European/German market frame. | Define Germany as the evidenced geographic starting point and Europe/EU/EEA as an exploratory boundary requiring channel and regulatory verification. | producer |

## Passed Checks

- ContextOps purpose and current stage are explicit.
- In-scope and out-of-scope boundaries are clear.
- The packet contains a working market definition.
- Core, adjacent, extended and excluded boundaries are present.
- Direct competitors, conventional alternatives, system alternatives, adjacent devices and non-switching are distinguished.
- The packet does not claim a comprehensive competitor census.
- Manufacturer and competitor performance claims are not presented as independent proof.
- The catalogue discrepancy is surfaced.
- German distribution evidence is dated.
- Wider European coverage is identified as uncertain.
- No segment priority, positioning, messaging, channel, campaign, SEO/GEO, sales, lifecycle or GTM recommendation leaks into the packet.
- Handoff questions preserve multiple possible segmentation bases without selecting one.
- Buying-context questions cover roles, triggers, comparison units, proof needs and observable signals.
- The status quo is retained as an alternative.
- The packet correctly warns against treating gauge alone as performance.
- Missing technical, clinical, regulatory and procurement evidence is visible.

## Missing Inputs Or Decisions

The following inputs are unavailable but do not block a market-context handoff once uncertainty is correctly labeled:

- IFU, label, declaration of conformity and intended-use documentation.
- Confirmed legal manufacturer, brand owner, authorized representative and distributor roles.
- Current manufacturer product master resolving the 25G catalogue discrepancy.
- Independent residual-volume and flow/extrusion-force testing.
- Clinical or controlled user evidence for comfort, bruising and adverse events.
- Customer, sales or procurement evidence about switching criteria.
- Confirmed geographic distribution and regulatory coverage outside Germany.

## Revision Instructions

1. Repair claim-level traceability across category labels, market boundaries and competitor examples.
2. Reclassify inferred purchasing and adoption dynamics as hypotheses.
3. Apply the regulated/sensitive claim-risk overlay without introducing external messaging or legal conclusions.
4. Clarify Germany as the evidenced geography and Europe as exploratory.
5. Add the explicit `Produces` field.
6. Preserve all passed scope boundaries, alternative clusters and downstream-neutral handoff questions.
7. Do not expand into buying-context conclusions, segmentation priority, positioning or strategy.

## Revalidation Scope

- Resolution of EVD-01 through EVD-03, CLM-01 and CTR-01.
- Claim-to-source traceability and uncertainty labels.
- Atomic risk treatment and allowed use for sensitive claims.
- Geographic boundary consistency.
- Preservation of passed checks and absence of new downstream leakage.

## Learning Signal

Case-specific signal: market packets in regulated or sensitive categories need a distinct separation between observable category language, inferred purchasing dynamics and externally usable claims. No profile or skill change is justified from this single case.
